silodosin

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

Silodosin carboxylic acid impurity (KMD-3293) is an inactive metabolite of silodosin. As its primary metabolite, it forms through the oxidation via alcohol and aldehyde dehydrogenases. Silodosin carboxylic acid impurity is utilized in research related to benign prostatic hyperplasia.

Dehydro silodosin (KMD-3241) is a selective α1A-adrenoceptor antagonist applicable in research on benign prostatic hyperplasia.

Silodosin glucuronide is an active metabolite of the α1A-adrenergic receptor antagonist silodosin . It is formed from silodosin by the UDP-glucuronosyltransferase (UGT) isoform UGT2B7. Silodosin glucuronide is toxic to rats with an LD50 value of 0.347 mg/kg.

5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate is a natural product that can be used as reference standards.

Silodosin-D4 is the deuterated form of Silodosin. Silodosin (T1504) (KAD 3213; KMD 3213) is a potent, selective, orally active α1A-adrenergic receptor (α1A-AR) antagonist. It exhibits high affinity for α1A-AR with a Ki of 0.036 nM, which is 162 and 50 times stronger compared to its affinities for α1B-AR and α1D-AR, with Ki values of 21 nM and 2.0 nM, respectively. Silodosin (T1504) is an effective and well-tolerated agent used in the research of LUTS/BPH.

Silodosin Sodium Salt-D6 (Racemic Mixture) (Standard) is a reference standard of Silodosin Sodium Salt-[D6], Racemic Mixture intended for quantitative analysis, quality control, and related biochemical research applications.